Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyNelfinavir
Targets (1)
Enzymes (8)
Carriers (1)
Transporters (5)
Identification
- Name
- Nelfinavir
- Accession Number
- DB00220 (APRD00003)
- Type
- Small Molecule
- Groups
- Approved
- Description
Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
- Structure
Structure for DB00220 (Nelfinavir)
- Synonyms
- Not Available
- External IDs
- AG1343
- Product Ingredients
Ingredient UNII CAS InChI Key Nelfinavir mesylate 98D603VP8V 159989-65-8 NQHXCOAXSHGTIA-SKXNDZRYSA-N - Product Images
- Approved Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Viracept Tablet, film coated 250 mg/1 Oral Agouron Pharmaceuticals 1997-03-14 Not applicable US 
Viracept Tablet, film coated 625 mg/1 Oral Remedy Repack 2013-03-27 2016-03-11 US 
Viracept Powder 50 mg/g Oral Agouron Pharmaceuticals 1997-03-14 2016-02-26 US Viracept Tablet 625 mg Oral Pfizer 2004-08-11 Not applicable Canada 
Viracept Tablet, film coated 250 mg/1 Oral H.J. Harkins Company 1997-03-14 Not applicable US 
Viracept Tablet, film coated 625 mg/1 Oral Agouron Pharmaceuticals 2003-04-30 Not applicable US Viracept Tablet, film coated 250 mg/1 Oral Pd Rx Pharmaceuticals, Inc. 1997-03-14 Not applicable US Viracept Tablet, film coated 625 mg/1 Oral State of Florida DOH Central Pharmacy 2009-07-01 Not applicable US Viracept -250mg Tablet 250 mg Oral Pfizer 1998-09-21 Not applicable Canada Viracept -50mg Powder 50 mg Oral Pfizer 1998-09-21 Not applicable Canada - Approved Generic Prescription Products
- Not Available
- Approved Over the Counter Products
- Not Available
- Unapproved/Other Products
- Not Available
- International/Other Brands
- Not Available
- Brand mixtures
- Not Available
- Categories
- Anti-HIV Agents
- Anti-Infective Agents
- Anti-Retroviral Agents
- Antiinfectives for Systemic Use
- Antiviral Agents
- Antivirals for Systemic Use
- BCRP/ABCG2 Inhibitors
- Combined Inhibitors of CYP3A4 and P-glycoprotein
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors (weak)
- Cytochrome P-450 CYP2B6 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors (moderate)
- Cytochrome P-450 CYP2C19 Substrates
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors
- Cytochrome P-450 CYP3A4 Inhibitors (strong)
- Cytochrome P-450 CYP3A4 Substrates
- Direct Acting Antivirals
- Enzyme Inhibitors
- HIV Protease Inhibitors
- Hyperglycemia-Associated Agents
- Isoquinolines
- P-glycoprotein/ABCB1 Inducers
- P-glycoprotein/ABCB1 Inhibitors
- P-glycoprotein/ABCB1 Substrates
- Protease Inhibitors
- QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying)
- UNII
- HO3OGH5D7I
- CAS number
- 159989-64-7
- Weight
- Average: 567.782
Monoisotopic: 567.313077633 - Chemical Formula
- C32H45N3O4S
- InChI Key
- QAGYKUNXZHXKMR-HKWSIXNMSA-N
- InChI
- InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1
- IUPAC Name
- (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylphenyl)formamido]-4-(phenylsulfanyl)butyl]-decahydroisoquinoline-3-carboxamide
- SMILES
- [H][[email protected]@]12CCCC[[email protected]]1([H])CN(C[[email protected]@H](O)[[email protected]](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[[email protected]@H](C2)C(=O)NC(C)(C)C
Pharmacology
- Indication
Used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
- Structured Indications
- Pharmacodynamics
Nelfinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
- Mechanism of action
Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
Target Actions Organism AHIV-1 protease inhibitorHuman immunodeficiency virus - Absorption
Well absorbed following oral administration.
- Volume of distribution
- 2 to 7 L/kg
- Protein binding
>98%
- Metabolism
Primarily hepatic via cytochrome P450 (CYP450) enzymes. CYP3A and CYP2C19 appear to be the predominant enzymes that metabolize nelfinavir in humans. One major and several minor metabolites are found in plasma; the major oxidative metabolite has in vitro antiviral activity comparable to that of the parent drug.
- Route of elimination
The terminal half-life in plasma was typically 3.5 to 5 hours. The majority (87%) of an oral 750 mg dose containing 14C-nelfinavir was recovered in the feces; fecal radioactivity consisted of numerous oxidative metabolites (78%) and unchanged nelfinavir (22%). Only 1–2% of the dose was recovered in urine, of which unchanged nelfinavir was the major component.
- Half life
3.5 - 5 hours
- Clearance
- Not Available
- Toxicity
Oral LD50 is over 5g/kg in rats. Side effects include thirst and hunger, unexplained weight loss, increased urination, fatigue, and dry, itchy skin.
- Affected organisms
- Human Immunodeficiency Virus
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 16-Bromoepiandrosterone The serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Nelfinavir. Investigational 19-norandrostenedione The serum concentration of 19-norandrostenedione can be increased when it is combined with Nelfinavir. Experimental, Illicit 2,4-thiazolidinedione The therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Nelfinavir. Investigational 5-androstenedione The serum concentration of 5-androstenedione can be increased when it is combined with Nelfinavir. Experimental, Illicit Abacavir The serum concentration of Abacavir can be decreased when it is combined with Nelfinavir. Approved, Investigational Abiraterone The metabolism of Abiraterone can be decreased when combined with Nelfinavir. Approved Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Nelfinavir. Approved, Investigational Acebutolol The serum concentration of Acebutolol can be decreased when it is combined with Nelfinavir. Approved Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Nelfinavir. Approved Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Nelfinavir. Approved Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Nelfinavir. Withdrawn Acetylsalicylic acid The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Nelfinavir. Approved, Vet Approved Adinazolam The metabolism of Adinazolam can be decreased when combined with Nelfinavir. Approved Afatinib The serum concentration of Afatinib can be decreased when it is combined with Nelfinavir. Approved AICA ribonucleotide The therapeutic efficacy of Aicar can be decreased when used in combination with Nelfinavir. Experimental Albendazole The metabolism of Albendazole can be decreased when combined with Nelfinavir. Approved, Vet Approved Alclometasone The metabolism of Alclometasone can be decreased when combined with Nelfinavir. Approved Aldosterone The serum concentration of Aldosterone can be decreased when it is combined with Nelfinavir. Experimental Alectinib The serum concentration of Nelfinavir can be increased when it is combined with Alectinib. Approved Alfentanil The metabolism of Alfentanil can be decreased when combined with Nelfinavir. Approved, Illicit Alfuzosin The serum concentration of Alfuzosin can be increased when it is combined with Nelfinavir. Approved, Investigational Aliskiren The metabolism of Aliskiren can be decreased when combined with Nelfinavir. Approved, Investigational Alitretinoin The serum concentration of Alitretinoin can be decreased when it is combined with Nelfinavir. Approved, Investigational Allylestrenol The metabolism of Allylestrenol can be decreased when combined with Nelfinavir. Approved Almotriptan The serum concentration of Almotriptan can be increased when it is combined with Nelfinavir. Approved, Investigational Alogliptin The metabolism of Alogliptin can be decreased when combined with Nelfinavir. Approved Alosetron The serum concentration of Alosetron can be increased when it is combined with Nelfinavir. Approved, Withdrawn Alprazolam The serum concentration of Alprazolam can be increased when it is combined with Nelfinavir. Approved, Illicit, Investigational Amantadine The serum concentration of Nelfinavir can be increased when it is combined with Amantadine. Approved Ambrisentan The metabolism of Ambrisentan can be decreased when combined with Nelfinavir. Approved, Investigational Ambroxol The metabolism of Ambroxol can be decreased when combined with Nelfinavir. Approved Ambroxol acefyllinate The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Nelfinavir. Experimental Amcinonide The serum concentration of Amcinonide can be increased when it is combined with Nelfinavir. Approved Amineptine The serum concentration of Amineptine can be increased when it is combined with Nelfinavir. Illicit, Withdrawn Aminohippuric acid The serum concentration of Nelfinavir can be increased when it is combined with Aminohippuric acid. Approved Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Nelfinavir. Approved, Withdrawn Aminophylline The metabolism of Aminophylline can be decreased when combined with Nelfinavir. Approved Amiodarone The serum concentration of Amiodarone can be increased when it is combined with Nelfinavir. Approved, Investigational Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Nelfinavir. Approved Amlodipine The metabolism of Amlodipine can be decreased when combined with Nelfinavir. Approved Amoxicillin The metabolism of Amoxicillin can be decreased when combined with Nelfinavir. Approved, Vet Approved Amprenavir The metabolism of Amprenavir can be decreased when combined with Nelfinavir. Approved Amsacrine The serum concentration of Nelfinavir can be increased when it is combined with Amsacrine. Approved Anagrelide Nelfinavir may increase the QTc-prolonging activities of Anagrelide. Approved Androstenedione The serum concentration of 4-Androstenedione can be increased when it is combined with Nelfinavir. Experimental, Illicit Anecortave The serum concentration of Anecortave can be increased when it is combined with Nelfinavir. Investigational Antipyrine The metabolism of Antipyrine can be decreased when combined with Nelfinavir. Approved Apixaban The serum concentration of Apixaban can be increased when it is combined with Nelfinavir. Approved Apremilast The metabolism of Apremilast can be decreased when combined with Nelfinavir. Approved, Investigational Aprepitant The serum concentration of Nelfinavir can be increased when it is combined with Aprepitant. Approved, Investigational Arformoterol The metabolism of Arformoterol can be decreased when combined with Nelfinavir. Approved, Investigational Argatroban The metabolism of Argatroban can be decreased when combined with Nelfinavir. Approved, Investigational Aripiprazole The serum concentration of Aripiprazole can be increased when it is combined with Nelfinavir. Approved, Investigational Armodafinil The metabolism of Nelfinavir can be decreased when combined with Armodafinil. Approved, Investigational Arsenic trioxide Nelfinavir may increase the QTc-prolonging activities of Arsenic trioxide. Approved, Investigational Artemether The metabolism of Artemether can be decreased when combined with Nelfinavir. Approved Asenapine The serum concentration of Nelfinavir can be decreased when it is combined with Asenapine. Approved Astemizole The serum concentration of Astemizole can be increased when it is combined with Nelfinavir. Approved, Withdrawn Atazanavir The metabolism of Atazanavir can be decreased when combined with Nelfinavir. Approved, Investigational Atenolol The serum concentration of Atenolol can be decreased when it is combined with Nelfinavir. Approved Atomoxetine The metabolism of Nelfinavir can be decreased when combined with Atomoxetine. Approved Atorvastatin The serum concentration of Atorvastatin can be increased when it is combined with Nelfinavir. Approved Avanafil The serum concentration of Avanafil can be increased when it is combined with Nelfinavir. Approved Axitinib The serum concentration of Axitinib can be increased when it is combined with Nelfinavir. Approved, Investigational Azelastine The metabolism of Azelastine can be decreased when combined with Nelfinavir. Approved Azithromycin The metabolism of Azithromycin can be decreased when combined with Nelfinavir. Approved Azithromycin The serum concentration of Azithromycin can be increased when it is combined with Nelfinavir. Approved Balaglitazone The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Nelfinavir. Investigational Banoxantrone The metabolism of Banoxantrone can be decreased when combined with Nelfinavir. Investigational Barnidipine The serum concentration of Barnidipine can be increased when it is combined with Nelfinavir. Approved Beclomethasone dipropionate The serum concentration of Beclomethasone dipropionate can be increased when it is combined with Nelfinavir. Approved, Investigational Bedaquiline The serum concentration of Bedaquiline can be increased when it is combined with Nelfinavir. Approved Benzatropine The metabolism of Benzatropine can be decreased when combined with Nelfinavir. Approved Benzocaine The serum concentration of Nelfinavir can be increased when it is combined with Benzocaine. Approved Benzphetamine The metabolism of Benzphetamine can be decreased when combined with Nelfinavir. Approved, Illicit Benzyl alcohol The metabolism of Benzyl alcohol can be decreased when combined with Nelfinavir. Approved Bepridil The serum concentration of Nelfinavir can be increased when it is combined with Bepridil. Approved, Withdrawn Betamethasone The serum concentration of Betamethasone can be decreased when it is combined with Nelfinavir. Approved, Vet Approved Bexarotene The metabolism of Bexarotene can be decreased when combined with Nelfinavir. Approved, Investigational Bezafibrate The metabolism of Bezafibrate can be decreased when combined with Nelfinavir. Approved Bicalutamide The metabolism of Bicalutamide can be decreased when combined with Nelfinavir. Approved Biperiden The serum concentration of Nelfinavir can be increased when it is combined with Biperiden. Approved Bisoprolol The metabolism of Bisoprolol can be decreased when combined with Nelfinavir. Approved Boceprevir The serum concentration of Nelfinavir can be decreased when it is combined with Boceprevir. Withdrawn Bortezomib The serum concentration of Bortezomib can be increased when it is combined with Nelfinavir. Approved, Investigational Bosentan The serum concentration of Bosentan can be increased when it is combined with Nelfinavir. Approved, Investigational Bosutinib The serum concentration of Bosutinib can be increased when it is combined with Nelfinavir. Approved Brentuximab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Nelfinavir. Approved Brexpiprazole The serum concentration of Brexpiprazole can be increased when it is combined with Nelfinavir. Approved Brinzolamide The serum concentration of Brinzolamide can be increased when it is combined with Nelfinavir. Approved Bromazepam The metabolism of Bromazepam can be decreased when combined with Nelfinavir. Approved, Illicit Bromocriptine The serum concentration of Bromocriptine can be increased when it is combined with Nelfinavir. Approved, Investigational Brompheniramine The metabolism of Brompheniramine can be decreased when combined with Nelfinavir. Approved Budesonide The serum concentration of Budesonide can be increased when it is combined with Nelfinavir. Approved Budesonide The metabolism of Budesonide can be decreased when combined with Nelfinavir. Approved Buformin The therapeutic efficacy of Buformin can be decreased when used in combination with Nelfinavir. Withdrawn Bupivacaine The metabolism of Bupivacaine can be decreased when combined with Nelfinavir. Approved, Investigational Buprenorphine The metabolism of Buprenorphine can be decreased when combined with Nelfinavir. Approved, Illicit, Investigational, Vet Approved Bupropion The metabolism of Bupropion can be decreased when combined with Nelfinavir. Approved Buspirone The metabolism of Buspirone can be decreased when combined with Nelfinavir. Approved, Investigational Busulfan The metabolism of Busulfan can be decreased when combined with Nelfinavir. Approved, Investigational Cabazitaxel The serum concentration of Cabazitaxel can be increased when it is combined with Nelfinavir. Approved Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Nelfinavir. Approved Cabozantinib The serum concentration of Cabozantinib can be increased when it is combined with Nelfinavir. Approved Caffeine The metabolism of Caffeine can be decreased when combined with Nelfinavir. Approved Calcitriol The metabolism of Calcitriol can be decreased when combined with Nelfinavir. Approved, Nutraceutical Camptothecin The serum concentration of Camptothecin can be decreased when it is combined with Nelfinavir. Experimental Canagliflozin The metabolism of Canagliflozin can be decreased when combined with Nelfinavir. Approved Candesartan The serum concentration of Nelfinavir can be increased when it is combined with Candesartan. Approved Captopril The serum concentration of Nelfinavir can be increased when it is combined with Captopril. Approved Carbamazepine The metabolism of Nelfinavir can be increased when combined with Carbamazepine. Approved, Investigational Carbinoxamine The metabolism of Carbinoxamine can be decreased when combined with Nelfinavir. Approved Carfilzomib The serum concentration of Carfilzomib can be decreased when it is combined with Nelfinavir. Approved Cariprazine The metabolism of Cariprazine can be decreased when combined with Nelfinavir. Approved Carisoprodol The metabolism of Carisoprodol can be decreased when combined with Nelfinavir. Approved Carvedilol The metabolism of Carvedilol can be decreased when combined with Nelfinavir. Approved, Investigational Caspofungin The serum concentration of Nelfinavir can be increased when it is combined with Caspofungin. Approved Castanospermine The therapeutic efficacy of Castanospermine can be decreased when used in combination with Nelfinavir. Experimental Celecoxib The metabolism of Celecoxib can be decreased when combined with Nelfinavir. Approved, Investigational Celiprolol The metabolism of Celiprolol can be decreased when combined with Nelfinavir. Approved, Investigational Cephalexin The metabolism of Cephalexin can be decreased when combined with Nelfinavir. Approved, Vet Approved Ceritinib The serum concentration of Ceritinib can be increased when it is combined with Nelfinavir. Approved Cerivastatin The metabolism of Cerivastatin can be decreased when combined with Nelfinavir. Withdrawn Cevimeline The metabolism of Cevimeline can be decreased when combined with Nelfinavir. Approved Chenodeoxycholic acid The metabolism of Chenodeoxycholic acid can be decreased when combined with Nelfinavir. Approved Chloramphenicol The metabolism of Nelfinavir can be decreased when combined with Chloramphenicol. Approved, Vet Approved Chlordiazepoxide The metabolism of Chlordiazepoxide can be decreased when combined with Nelfinavir. Approved, Illicit Chloroquine The metabolism of Chloroquine can be decreased when combined with Nelfinavir. Approved, Vet Approved Chlorotrianisene The serum concentration of Chlorotrianisene can be decreased when it is combined with Nelfinavir. Withdrawn Chlorphenamine The metabolism of Chlorphenamine can be decreased when combined with Nelfinavir. Approved Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Nelfinavir. Approved, Vet Approved Chlorpropamide The serum concentration of Nelfinavir can be increased when it is combined with Chlorpropamide. Approved Chlorprothixene The serum concentration of Nelfinavir can be increased when it is combined with Chlorprothixene. Approved, Withdrawn Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Nelfinavir. Approved Cholecalciferol The metabolism of Cholecalciferol can be decreased when combined with Nelfinavir. Approved, Nutraceutical Cholesterol The serum concentration of Nelfinavir can be increased when it is combined with Cholesterol. Experimental Cholic Acid The serum concentration of Nelfinavir can be decreased when it is combined with Cholic Acid. Approved Ciclesonide The metabolism of Ciclesonide can be decreased when combined with Nelfinavir. Approved, Investigational Ciglitazone The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Nelfinavir. Experimental Cilazapril The serum concentration of Nelfinavir can be increased when it is combined with Cilazapril. Approved Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Nelfinavir. Approved Cimetidine The serum concentration of Nelfinavir can be decreased when it is combined with Cimetidine. Approved Cinacalcet The metabolism of Cinacalcet can be decreased when combined with Nelfinavir. Approved Ciprofloxacin Nelfinavir may increase the QTc-prolonging activities of Ciprofloxacin. Approved, Investigational Cisapride The serum concentration of Cisapride can be increased when it is combined with Nelfinavir. Approved, Investigational, Withdrawn Cisplatin The serum concentration of Cisplatin can be decreased when it is combined with Nelfinavir. Approved Citalopram The serum concentration of Citalopram can be increased when it is combined with Nelfinavir. Approved Clarithromycin The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Nelfinavir. Approved Clemastine The metabolism of Nelfinavir can be decreased when combined with Clemastine. Approved Clindamycin The metabolism of Clindamycin can be decreased when combined with Nelfinavir. Approved, Vet Approved Clobazam The metabolism of Clobazam can be decreased when combined with Nelfinavir. Approved, Illicit Clobetasol The serum concentration of Clobetasol can be increased when it is combined with Nelfinavir. Investigational Clobetasol propionate The serum concentration of Clobetasol propionate can be increased when it is combined with Nelfinavir. Approved Clocortolone The serum concentration of Clocortolone can be increased when it is combined with Nelfinavir. Approved Clofazimine The metabolism of Clofazimine can be decreased when combined with Nelfinavir. Approved, Investigational Clofibrate The metabolism of Clofibrate can be decreased when combined with Nelfinavir. Approved clomethiazole The metabolism of clomethiazole can be decreased when combined with Nelfinavir. Investigational Clomifene The serum concentration of Clomifene can be decreased when it is combined with Nelfinavir. Approved, Investigational Clomipramine The metabolism of Clomipramine can be decreased when combined with Nelfinavir. Approved, Vet Approved Clonazepam The metabolism of Clonazepam can be decreased when combined with Nelfinavir. Approved, Illicit Clonidine The metabolism of Clonidine can be decreased when combined with Nelfinavir. Approved Clopidogrel The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Nelfinavir resulting in a loss in efficacy. Approved, Nutraceutical Clorazepate The metabolism of Clorazepate can be decreased when combined with Nelfinavir. Approved, Illicit Clotiazepam The metabolism of Clotiazepam can be decreased when combined with Nelfinavir. Approved, Illicit Clotrimazole The metabolism of Nelfinavir can be decreased when combined with Clotrimazole. Approved, Vet Approved Clozapine The metabolism of Clozapine can be decreased when combined with Nelfinavir. Approved Cobicistat The metabolism of Nelfinavir can be decreased when combined with Cobicistat. Approved Cobimetinib The serum concentration of Cobimetinib can be increased when it is combined with Nelfinavir. Approved Cocaine The metabolism of Cocaine can be decreased when combined with Nelfinavir. Approved, Illicit Codeine The metabolism of Codeine can be decreased when combined with Nelfinavir. Approved, Illicit Colchicine The serum concentration of Colchicine can be increased when it is combined with Nelfinavir. Approved Colforsin The serum concentration of Nelfinavir can be increased when it is combined with Colforsin. Experimental Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Nelfinavir. Approved, Investigational Conjugated estrogens The metabolism of Conjugated Equine Estrogens can be decreased when combined with Nelfinavir. Approved Cortisone acetate The metabolism of Cortisone acetate can be decreased when combined with Nelfinavir. Approved Crizotinib The serum concentration of Crizotinib can be increased when it is combined with Nelfinavir. Approved Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Nelfinavir. Approved Cyclophosphamide The risk or severity of adverse effects can be increased when Nelfinavir is combined with Cyclophosphamide. Approved, Investigational Cyclosporine The serum concentration of Cyclosporine can be increased when it is combined with Nelfinavir. Approved, Investigational, Vet Approved Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Cytarabine The metabolism of Cytarabine can be decreased when combined with Nelfinavir. Approved, Investigational Dabigatran etexilate The serum concentration of Dabigatran etexilate can be decreased when it is combined with Nelfinavir. Approved Dabrafenib The serum concentration of Nelfinavir can be decreased when it is combined with Dabrafenib. Approved Daclatasvir The serum concentration of Daclatasvir can be increased when it is combined with Nelfinavir. Approved Dactinomycin The serum concentration of Dactinomycin can be decreased when it is combined with Nelfinavir. Approved Dantrolene The metabolism of Dantrolene can be decreased when combined with Nelfinavir. Approved Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Nelfinavir. Approved Dapoxetine The serum concentration of Dapoxetine can be increased when it is combined with Nelfinavir. Investigational Dapsone The metabolism of Dapsone can be decreased when combined with Nelfinavir. Approved, Investigational Darifenacin The metabolism of Darifenacin can be decreased when combined with Nelfinavir. Approved, Investigational Darunavir The metabolism of Darunavir can be decreased when combined with Nelfinavir. Approved Dasabuvir The metabolism of Dasabuvir can be decreased when combined with Nelfinavir. Approved Dasatinib The serum concentration of Dasatinib can be increased when it is combined with Nelfinavir. Approved, Investigational Daunorubicin The metabolism of Daunorubicin can be decreased when combined with Nelfinavir. Approved Debrisoquin The serum concentration of Debrisoquin can be decreased when it is combined with Nelfinavir. Approved Deferasirox The serum concentration of Nelfinavir can be decreased when it is combined with Deferasirox. Approved, Investigational Delavirdine The serum concentration of Delavirdine can be decreased when it is combined with Nelfinavir. Approved Deoxyspergualin The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Nelfinavir. Investigational Desipramine The serum concentration of Desipramine can be increased when it is combined with Nelfinavir. Approved Desloratadine The serum concentration of Nelfinavir can be increased when it is combined with Desloratadine. Approved, Investigational Desogestrel The serum concentration of Desogestrel can be decreased when it is combined with Nelfinavir. Approved Desoximetasone The serum concentration of Desoximetasone can be increased when it is combined with Nelfinavir. Approved Desoxycorticosterone acetate The serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Nelfinavir. Approved Desoxycorticosterone Pivalate The serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Nelfinavir. Experimental, Vet Approved Desvenlafaxine The metabolism of Desvenlafaxine can be decreased when combined with Nelfinavir. Approved Dexamethasone The metabolism of Dexamethasone can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Dexamethasone isonicotinate The serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Nelfinavir. Vet Approved Dexlansoprazole The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with TAK-390MR resulting in a loss in efficacy. Approved Dextromethorphan The metabolism of Dextromethorphan can be decreased when combined with Nelfinavir. Approved Dextropropoxyphene The metabolism of Dextropropoxyphene can be decreased when combined with Nelfinavir. Approved, Illicit, Withdrawn Diazepam The metabolism of Diazepam can be decreased when combined with Nelfinavir. Approved, Illicit, Vet Approved Diclofenac The metabolism of Diclofenac can be decreased when combined with Nelfinavir. Approved, Vet Approved Dienestrol The serum concentration of Dienestrol can be decreased when it is combined with Nelfinavir. Approved Dienogest The serum concentration of Dienogest can be decreased when it is combined with Nelfinavir. Approved Diethylstilbestrol The serum concentration of Diethylstilbestrol can be decreased when it is combined with Nelfinavir. Approved Diflorasone The serum concentration of Diflorasone can be increased when it is combined with Nelfinavir. Approved Difluocortolone The serum concentration of Difluocortolone can be increased when it is combined with Nelfinavir. Approved Difluprednate The serum concentration of Difluprednate can be increased when it is combined with Nelfinavir. Approved Digitoxin The metabolism of Digitoxin can be decreased when combined with Nelfinavir. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with Nelfinavir. Approved Dihydrocodeine The metabolism of Dihydrocodeine can be decreased when combined with Nelfinavir. Approved, Illicit Dihydroergotamine The serum concentration of Dihydroergotamine can be increased when it is combined with Nelfinavir. Approved Dihydrotestosterone The serum concentration of Dihydrotestosterone can be decreased when it is combined with Nelfinavir. Illicit Diltiazem The metabolism of Diltiazem can be decreased when combined with Nelfinavir. Approved Diphenhydramine The metabolism of Diphenhydramine can be decreased when combined with Nelfinavir. Approved Dipyridamole The serum concentration of Dipyridamole can be decreased when it is combined with Nelfinavir. Approved Disopyramide The metabolism of Disopyramide can be decreased when combined with Nelfinavir. Approved Disulfiram The metabolism of Disulfiram can be decreased when combined with Nelfinavir. Approved Docetaxel The metabolism of Docetaxel can be decreased when combined with Nelfinavir. Approved, Investigational Dofetilide The serum concentration of Dofetilide can be increased when it is combined with Nelfinavir. Approved Dolasetron The metabolism of Dolasetron can be decreased when combined with Nelfinavir. Approved Domperidone The serum concentration of Domperidone can be increased when it is combined with Nelfinavir. Approved, Investigational, Vet Approved Donepezil The metabolism of Donepezil can be decreased when combined with Nelfinavir. Approved Dopamine The metabolism of Dopamine can be decreased when combined with Nelfinavir. Approved Dorzolamide The metabolism of Dorzolamide can be decreased when combined with Nelfinavir. Approved Dosulepin The serum concentration of Dosulepin can be increased when it is combined with Nelfinavir. Approved Doxazosin The serum concentration of Nelfinavir can be increased when it is combined with Doxazosin. Approved Doxepin The serum concentration of Nelfinavir can be decreased when it is combined with Doxepin. Approved Doxorubicin The serum concentration of Doxorubicin can be increased when it is combined with Nelfinavir. Approved, Investigational Doxorubicin The metabolism of Doxorubicin can be decreased when combined with Nelfinavir. Approved, Investigational Doxycycline The metabolism of Nelfinavir can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Nelfinavir. Approved, Illicit Dronedarone The serum concentration of Dronedarone can be increased when it is combined with Nelfinavir. Approved Droperidol Nelfinavir may increase the QTc-prolonging activities of Droperidol. Approved, Vet Approved Drospirenone The serum concentration of Drospirenone can be decreased when it is combined with Nelfinavir. Approved Dulaglutide The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Nelfinavir. Approved Dutasteride The serum concentration of Dutasteride can be increased when it is combined with Nelfinavir. Approved, Investigational Dyphylline The serum concentration of Dyphylline can be decreased when it is combined with Nelfinavir. Approved Edoxaban The serum concentration of Edoxaban can be increased when it is combined with Nelfinavir. Approved Efavirenz The metabolism of Efavirenz can be decreased when combined with Nelfinavir. Approved, Investigational Elbasvir The serum concentration of Nelfinavir can be increased when it is combined with Elbasvir. Approved Eletriptan The serum concentration of Eletriptan can be increased when it is combined with Nelfinavir. Approved, Investigational Eliglustat The serum concentration of Eliglustat can be increased when it is combined with Nelfinavir. Approved Elvitegravir The metabolism of Elvitegravir can be decreased when combined with Nelfinavir. Approved Empagliflozin The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nelfinavir. Approved Enalapril The metabolism of Enalapril can be decreased when combined with Nelfinavir. Approved, Vet Approved Enfuvirtide The serum concentration of Enfuvirtide can be increased when it is combined with Nelfinavir. Approved, Investigational Enzalutamide The serum concentration of Nelfinavir can be decreased when it is combined with Enzalutamide. Approved Epinastine The serum concentration of Nelfinavir can be decreased when it is combined with Epinastine. Approved, Investigational Eplerenone The serum concentration of Eplerenone can be increased when it is combined with Nelfinavir. Approved Equilenin The serum concentration of Equilenin can be increased when it is combined with Nelfinavir. Experimental Equilin The serum concentration of Equilin can be increased when it is combined with Nelfinavir. Approved Ergocalciferol The metabolism of Ergocalciferol can be decreased when combined with Nelfinavir. Approved, Nutraceutical Ergoloid mesylate The serum concentration of Ergoloid mesylate can be increased when it is combined with Nelfinavir. Approved Ergonovine The serum concentration of Ergonovine can be increased when it is combined with Nelfinavir. Approved Ergotamine The serum concentration of Ergotamine can be increased when it is combined with Nelfinavir. Approved Erlotinib The serum concentration of Erlotinib can be increased when it is combined with Nelfinavir. Approved, Investigational Erythromycin The metabolism of Erythromycin can be decreased when combined with Nelfinavir. Approved, Vet Approved Escitalopram The metabolism of Escitalopram can be decreased when combined with Nelfinavir. Approved, Investigational Eslicarbazepine acetate The serum concentration of Nelfinavir can be decreased when it is combined with Eslicarbazepine acetate. Approved Esmirtazapine The serum concentration of Esmirtazapine can be increased when it is combined with Nelfinavir. Investigational Esomeprazole The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Esomeprazole resulting in a loss in efficacy. Approved, Investigational Estazolam The serum concentration of Estazolam can be increased when it is combined with Nelfinavir. Approved, Illicit Estradiol The metabolism of Estradiol can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Estradiol valerate/Dienogest The metabolism of Estradiol valerate/Dienogest can be decreased when combined with Nelfinavir. Approved Estramustine The metabolism of Estramustine can be decreased when combined with Nelfinavir. Approved Estriol The serum concentration of Estriol can be decreased when it is combined with Nelfinavir. Approved, Vet Approved Estrogens, esterified The serum concentration of Estrogens, esterified can be decreased when it is combined with Nelfinavir. Approved Estrone The metabolism of Estrone can be decreased when combined with Nelfinavir. Approved Estrone sulfate The metabolism of Estrone sulfate can be decreased when combined with Nelfinavir. Approved Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Nelfinavir. Approved Ethanol The metabolism of Ethanol can be decreased when combined with Nelfinavir. Approved Ethinyl Estradiol The metabolism of Ethinyl Estradiol can be decreased when combined with Nelfinavir. Approved Ethosuximide The metabolism of Ethosuximide can be decreased when combined with Nelfinavir. Approved Ethylmorphine The metabolism of Ethylmorphine can be decreased when combined with Nelfinavir. Approved, Illicit Ethynodiol diacetate The serum concentration of Ethynodiol diacetate can be decreased when it is combined with Nelfinavir. Approved Etizolam The serum concentration of Etizolam can be increased when it is combined with Nelfinavir. Approved Etonogestrel The serum concentration of Etonogestrel can be decreased when it is combined with Nelfinavir. Approved, Investigational Etoposide The metabolism of Etoposide can be decreased when combined with Nelfinavir. Approved Etoricoxib The metabolism of Etoricoxib can be decreased when combined with Nelfinavir. Approved, Investigational Etravirine The serum concentration of Etravirine can be decreased when it is combined with Nelfinavir. Approved Everolimus The serum concentration of Everolimus can be increased when it is combined with Nelfinavir. Approved Exemestane The metabolism of Exemestane can be decreased when combined with Nelfinavir. Approved, Investigational Exenatide The therapeutic efficacy of Exenatide can be decreased when used in combination with Nelfinavir. Approved, Investigational Ezetimibe The serum concentration of Ezetimibe can be decreased when it is combined with Nelfinavir. Approved Famciclovir The metabolism of Famciclovir can be decreased when combined with Nelfinavir. Approved Famotidine The serum concentration of Nelfinavir can be decreased when it is combined with Famotidine. Approved Felbamate The metabolism of Felbamate can be decreased when combined with Nelfinavir. Approved Felodipine The metabolism of Felodipine can be decreased when combined with Nelfinavir. Approved, Investigational Fenofibrate The metabolism of Fenofibrate can be decreased when combined with Nelfinavir. Approved Fentanyl The serum concentration of Fentanyl can be increased when it is combined with Nelfinavir. Approved, Illicit, Investigational, Vet Approved Fesoterodine The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nelfinavir. Approved Fexofenadine The serum concentration of Fexofenadine can be decreased when it is combined with Nelfinavir. Approved Fidaxomicin The serum concentration of Fidaxomicin can be decreased when it is combined with Nelfinavir. Approved Finasteride The metabolism of Finasteride can be decreased when combined with Nelfinavir. Approved Fingolimod The metabolism of Fingolimod can be decreased when combined with Nelfinavir. Approved, Investigational Flecainide Nelfinavir may increase the QTc-prolonging activities of Flecainide. Approved, Withdrawn Flibanserin The serum concentration of Flibanserin can be increased when it is combined with Nelfinavir. Approved fluasterone The serum concentration of fluasterone can be increased when it is combined with Nelfinavir. Investigational Fluconazole The metabolism of Nelfinavir can be decreased when combined with Fluconazole. Approved Fludrocortisone The serum concentration of Fludrocortisone can be increased when it is combined with Nelfinavir. Approved Flumethasone The serum concentration of Flumethasone can be increased when it is combined with Nelfinavir. Approved, Vet Approved Flunisolide The metabolism of Flunisolide can be decreased when combined with Nelfinavir. Approved, Investigational Flunitrazepam The metabolism of Flunitrazepam can be decreased when combined with Nelfinavir. Approved, Illicit Fluocinolone Acetonide The serum concentration of Fluocinolone Acetonide can be increased when it is combined with Nelfinavir. Approved, Investigational, Vet Approved Fluocinonide The serum concentration of Fluocinonide can be increased when it is combined with Nelfinavir. Approved, Investigational Fluocortolone The serum concentration of Fluocortolone can be increased when it is combined with Nelfinavir. Approved, Withdrawn Fluorometholone The metabolism of Fluorometholone can be decreased when combined with Nelfinavir. Approved Fluoxetine The metabolism of Fluoxetine can be decreased when combined with Nelfinavir. Approved, Vet Approved Flupentixol Nelfinavir may increase the QTc-prolonging activities of Flupentixol. Approved, Withdrawn Fluphenazine The serum concentration of Nelfinavir can be increased when it is combined with Fluphenazine. Approved Fluprednidene The serum concentration of Fluprednidene can be increased when it is combined with Nelfinavir. Approved, Withdrawn Fluprednisolone The serum concentration of Fluprednisolone can be increased when it is combined with Nelfinavir. Approved Flurandrenolide The serum concentration of Flurandrenolide can be increased when it is combined with Nelfinavir. Approved Flurazepam The metabolism of Flurazepam can be decreased when combined with Nelfinavir. Approved, Illicit Flutamide The metabolism of Flutamide can be decreased when combined with Nelfinavir. Approved Fluticasone furoate The metabolism of Fluticasone furoate can be decreased when combined with Nelfinavir. Approved Fluticasone propionate The serum concentration of Fluticasone Propionate can be increased when it is combined with Nelfinavir. Approved Fluticasone propionate The metabolism of Fluticasone Propionate can be decreased when combined with Nelfinavir. Approved Fluvastatin The metabolism of Fluvastatin can be decreased when combined with Nelfinavir. Approved Fluvoxamine The metabolism of Nelfinavir can be decreased when combined with Fluvoxamine. Approved, Investigational Formestane The serum concentration of Formestane can be increased when it is combined with Nelfinavir. Approved, Investigational, Withdrawn Formoterol The metabolism of Formoterol can be decreased when combined with Nelfinavir. Approved, Investigational Fosamprenavir The metabolism of Fosamprenavir can be decreased when combined with Nelfinavir. Approved Fosaprepitant The serum concentration of Nelfinavir can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Nelfinavir can be decreased when it is combined with Fosphenytoin. Approved Fulvestrant The metabolism of Fulvestrant can be decreased when combined with Nelfinavir. Approved, Investigational Fusidic Acid The serum concentration of Nelfinavir can be increased when it is combined with Fusidic Acid. Approved Gadobenic acid Nelfinavir may increase the QTc-prolonging activities of Gadobenic acid. Approved Galantamine The metabolism of Galantamine can be decreased when combined with Nelfinavir. Approved Garlic The serum concentration of Nelfinavir can be decreased when it is combined with Garlic. Approved Gefitinib The metabolism of Gefitinib can be decreased when combined with Nelfinavir. Approved, Investigational Gemcitabine The serum concentration of Gemcitabine can be decreased when it is combined with Nelfinavir. Approved Gemfibrozil The metabolism of Gemfibrozil can be decreased when combined with Nelfinavir. Approved Gemifloxacin Nelfinavir may increase the QTc-prolonging activities of Gemifloxacin. Approved, Investigational Genistein The serum concentration of Nelfinavir can be increased when it is combined with Genistein. Investigational Gestodene The serum concentration of Gestodene can be decreased when it is combined with Nelfinavir. Approved Glibornuride The therapeutic efficacy of Glibornuride can be decreased when used in combination with Nelfinavir. Withdrawn Gliclazide The metabolism of Gliclazide can be decreased when combined with Nelfinavir. Approved Glimepiride The therapeutic efficacy of Glimepiride can be decreased when used in combination with Nelfinavir. Approved Glipizide The metabolism of Glipizide can be decreased when combined with Nelfinavir. Approved Gliquidone The therapeutic efficacy of Gliquidone can be decreased when used in combination with Nelfinavir. Approved Glucosamine The metabolism of Glucosamine can be decreased when combined with Nelfinavir. Approved Glyburide The metabolism of Glyburide can be decreased when combined with Nelfinavir. Approved Goserelin Nelfinavir may increase the QTc-prolonging activities of Goserelin. Approved Gramicidin D The serum concentration of Nelfinavir can be increased when it is combined with Gramicidin D. Approved Granisetron The metabolism of Granisetron can be decreased when combined with Nelfinavir. Approved, Investigational Grazoprevir The serum concentration of Grazoprevir can be decreased when it is combined with Nelfinavir. Approved Grepafloxacin The metabolism of Grepafloxacin can be decreased when combined with Nelfinavir. Withdrawn Guanfacine The serum concentration of Guanfacine can be increased when it is combined with Nelfinavir. Approved, Investigational Gusperimus The therapeutic efficacy of Gusperimus can be decreased when used in combination with Nelfinavir. Investigational Halofantrine The serum concentration of Halofantrine can be increased when it is combined with Nelfinavir. Approved Haloperidol The metabolism of Haloperidol can be decreased when combined with Nelfinavir. Approved Halothane The metabolism of Halothane can be decreased when combined with Nelfinavir. Approved, Vet Approved HE3286 The serum concentration of HE3286 can be increased when it is combined with Nelfinavir. Investigational Hexestrol The serum concentration of Hexestrol can be decreased when it is combined with Nelfinavir. Withdrawn Hexobarbital The metabolism of Hexobarbital can be decreased when combined with Nelfinavir. Approved Histamine The metabolism of Histamine Phosphate can be decreased when combined with Nelfinavir. Approved, Investigational Hydrocodone The serum concentration of Hydrocodone can be increased when it is combined with Nelfinavir. Approved, Illicit Hydrocortisone The metabolism of Hydrocortisone can be decreased when combined with Nelfinavir. Approved, Vet Approved Hydromorphone The metabolism of Hydromorphone can be decreased when combined with Nelfinavir. Approved, Illicit Hydroxyprogesterone caproate The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Nelfinavir. Approved Ibrutinib The serum concentration of Ibrutinib can be increased when it is combined with Nelfinavir. Approved Ibuprofen The serum concentration of Ibuprofen can be decreased when it is combined with Nelfinavir. Approved Ibutilide Nelfinavir may increase the QTc-prolonging activities of Ibutilide. Approved Idelalisib The serum concentration of Nelfinavir can be increased when it is combined with Idelalisib. Approved Ifosfamide The serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Nelfinavir resulting in a loss in efficacy. Approved Iloperidone The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Nelfinavir. Approved Imatinib The serum concentration of Imatinib can be increased when it is combined with Nelfinavir. Approved Imidafenacin The serum concentration of Imidafenacin can be increased when it is combined with Nelfinavir. Approved Imipramine The metabolism of Imipramine can be decreased when combined with Nelfinavir. Approved Imiquimod The metabolism of Imiquimod can be decreased when combined with Nelfinavir. Approved, Investigational Indacaterol The metabolism of Indacaterol can be decreased when combined with Nelfinavir. Approved Indapamide The metabolism of Indapamide can be decreased when combined with Nelfinavir. Approved Indinavir The metabolism of Indinavir can be decreased when combined with Nelfinavir. Approved Indomethacin The serum concentration of Indomethacin can be decreased when it is combined with Nelfinavir. Approved, Investigational Insulin Aspart The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Nelfinavir. Approved Insulin Detemir The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Nelfinavir. Approved Insulin Glargine The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Nelfinavir. Approved Insulin Glulisine The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Nelfinavir. Approved Insulin Lispro The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Nelfinavir. Approved Insulin Pork The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Nelfinavir. Approved Ipratropium bromide The metabolism of Ipratropium bromide can be decreased when combined with Nelfinavir. Approved Irinotecan The serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Nelfinavir. Approved, Investigational Isavuconazonium The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Nelfinavir. Approved, Investigational Isoniazid The metabolism of Nelfinavir can be decreased when combined with Isoniazid. Approved Isosorbide Dinitrate The metabolism of Isosorbide Dinitrate can be decreased when combined with Nelfinavir. Approved Isosorbide Mononitrate The metabolism of Isosorbide Mononitrate can be decreased when combined with Nelfinavir. Approved Isradipine The metabolism of Isradipine can be decreased when combined with Nelfinavir. Approved Istaroxime The serum concentration of Istaroxime can be increased when it is combined with Nelfinavir. Investigational Itraconazole The metabolism of Itraconazole can be decreased when combined with Nelfinavir. Approved, Investigational Ivabradine The serum concentration of Ivabradine can be increased when it is combined with Nelfinavir. Approved Ivacaftor The serum concentration of Ivacaftor can be increased when it is combined with Nelfinavir. Approved Ivermectin The metabolism of Ivermectin can be decreased when combined with Nelfinavir. Approved, Vet Approved Ixabepilone The serum concentration of Ixabepilone can be increased when it is combined with Nelfinavir. Approved, Investigational Ixazomib The metabolism of Ixazomib can be decreased when combined with Nelfinavir. Approved Ketamine The metabolism of Ketamine can be decreased when combined with Nelfinavir. Approved, Vet Approved Ketazolam The metabolism of Ketazolam can be decreased when combined with Nelfinavir. Approved Ketobemidone The metabolism of Ketobemidone can be decreased when combined with Nelfinavir. Approved Ketoconazole The metabolism of Ketoconazole can be decreased when combined with Nelfinavir. Approved, Investigational Lacosamide The serum concentration of Lacosamide can be increased when it is combined with Nelfinavir. Approved Lamivudine The serum concentration of Lamivudine can be decreased when it is combined with Nelfinavir. Approved, Investigational Lamotrigine The serum concentration of Lamotrigine can be decreased when it is combined with Nelfinavir. Approved, Investigational Lansoprazole The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Lansoprazole resulting in a loss in efficacy. Approved, Investigational Lapatinib The serum concentration of Lapatinib can be increased when it is combined with Nelfinavir. Approved, Investigational Laquinimod The metabolism of Laquinimod can be decreased when combined with Nelfinavir. Investigational Ledipasvir The serum concentration of Ledipasvir can be decreased when it is combined with Nelfinavir. Approved Lenalidomide The serum concentration of Lenalidomide can be decreased when it is combined with Nelfinavir. Approved Lenvatinib The metabolism of Lenvatinib can be decreased when combined with Nelfinavir. Approved Lercanidipine The serum concentration of Lercanidipine can be increased when it is combined with Nelfinavir. Approved, Investigational Letrozole The metabolism of Letrozole can be decreased when combined with Nelfinavir. Approved, Investigational Leuprolide Nelfinavir may increase the QTc-prolonging activities of Leuprolide. Approved, Investigational Levetiracetam The serum concentration of Levetiracetam can be decreased when it is combined with Nelfinavir. Approved, Investigational Levobupivacaine The serum concentration of Levobupivacaine can be increased when it is combined with Nelfinavir. Approved Levocetirizine The metabolism of Levocetirizine can be decreased when combined with Nelfinavir. Approved Levofloxacin Nelfinavir may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Levomethadyl Acetate The metabolism of Levomethadyl Acetate can be decreased when combined with Nelfinavir. Approved Levomilnacipran The serum concentration of Levomilnacipran can be increased when it is combined with Nelfinavir. Approved Levonorgestrel The serum concentration of Levonorgestrel can be decreased when it is combined with Nelfinavir. Approved, Investigational Levothyroxine The metabolism of Levothyroxine can be decreased when combined with Nelfinavir. Approved Lidocaine The metabolism of Lidocaine can be decreased when combined with Nelfinavir. Approved, Vet Approved Linagliptin The serum concentration of Linagliptin can be decreased when it is combined with Nelfinavir. Approved Liothyronine The serum concentration of Nelfinavir can be decreased when it is combined with Liothyronine. Approved, Vet Approved Liotrix The serum concentration of Nelfinavir can be decreased when it is combined with Liotrix. Approved Liraglutide The therapeutic efficacy of Liraglutide can be decreased when used in combination with Nelfinavir. Approved Lisinopril The serum concentration of Nelfinavir can be increased when it is combined with Lisinopril. Approved, Investigational Lisuride The metabolism of Lisuride can be decreased when combined with Nelfinavir. Approved Lomitapide The serum concentration of Lomitapide can be increased when it is combined with Nelfinavir. Approved Loperamide The metabolism of Loperamide can be decreased when combined with Nelfinavir. Approved Lopinavir The serum concentration of Lopinavir can be decreased when it is combined with Nelfinavir. Approved Loratadine The metabolism of Loratadine can be decreased when combined with Nelfinavir. Approved Lorcaserin The metabolism of Lorcaserin can be decreased when combined with Nelfinavir. Approved Losartan The metabolism of Losartan can be decreased when combined with Nelfinavir. Approved Lovastatin The serum concentration of Lovastatin can be increased when it is combined with Nelfinavir. Approved, Investigational Luliconazole The serum concentration of Nelfinavir can be increased when it is combined with Luliconazole. Approved Lumacaftor The serum concentration of Nelfinavir can be decreased when it is combined with Lumacaftor. Approved Lumefantrine The serum concentration of Lumefantrine can be increased when it is combined with Nelfinavir. Approved Lumiracoxib The metabolism of Lumiracoxib can be decreased when combined with Nelfinavir. Approved, Investigational Lurasidone The serum concentration of Lurasidone can be increased when it is combined with Nelfinavir. Approved Lynestrenol The serum concentration of Lynestrenol can be decreased when it is combined with Nelfinavir. Investigational Macitentan The serum concentration of Macitentan can be increased when it is combined with Nelfinavir. Approved Mannitol The serum concentration of Mannitol can be decreased when it is combined with Nelfinavir. Approved, Investigational Maprotiline The serum concentration of Nelfinavir can be increased when it is combined with Maprotiline. Approved Maraviroc The serum concentration of Maraviroc can be increased when it is combined with Nelfinavir. Approved, Investigational ME-609 The serum concentration of ME-609 can be increased when it is combined with Nelfinavir. Investigational Mebendazole The metabolism of Mebendazole can be decreased when combined with Nelfinavir. Approved, Vet Approved Medroxyprogesterone acetate The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Nelfinavir. Approved, Investigational Medrysone The serum concentration of Medrysone can be increased when it is combined with Nelfinavir. Approved Mefloquine The metabolism of Mefloquine can be decreased when combined with Nelfinavir. Approved Megestrol acetate The serum concentration of Nelfinavir can be increased when it is combined with Megestrol acetate. Approved, Vet Approved Melatonin The metabolism of Melatonin can be decreased when combined with Nelfinavir. Approved, Nutraceutical, Vet Approved Melengestrol The serum concentration of Melengestrol can be increased when it is combined with Nelfinavir. Vet Approved Meloxicam The metabolism of Meloxicam can be decreased when combined with Nelfinavir. Approved, Vet Approved Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Nelfinavir. Investigational, Withdrawn Meprobamate The serum concentration of Nelfinavir can be increased when it is combined with Meprobamate. Approved, Illicit Mestranol The serum concentration of Mestranol can be decreased when it is combined with Nelfinavir. Approved Metformin The therapeutic efficacy of Metformin can be decreased when used in combination with Nelfinavir. Approved Methadone The serum concentration of Methadone can be decreased when it is combined with Nelfinavir. Approved Methallenestril The serum concentration of Methallenestril can be decreased when it is combined with Nelfinavir. Experimental Methantheline The serum concentration of Nelfinavir can be decreased when it is combined with Methantheline. Approved Methaqualone The metabolism of Methaqualone can be decreased when combined with Nelfinavir. Illicit, Withdrawn Methotrexate The serum concentration of Methotrexate can be decreased when it is combined with Nelfinavir. Approved Methoxsalen The metabolism of Methoxsalen can be decreased when combined with Nelfinavir. Approved Methoxyflurane The metabolism of Methoxyflurane can be decreased when combined with Nelfinavir. Approved, Vet Approved Methsuximide The metabolism of Methsuximide can be decreased when combined with Nelfinavir. Approved Methylphenobarbital The metabolism of Methylphenobarbital can be decreased when combined with Nelfinavir. Approved Methylprednisolone The serum concentration of Methylprednisolone can be increased when it is combined with Nelfinavir. Approved, Vet Approved Methyltestosterone The metabolism of Methyltestosterone can be decreased when combined with Nelfinavir. Approved Metiamide The serum concentration of Nelfinavir can be decreased when it is combined with Metiamide. Experimental Metoprolol The serum concentration of Metoprolol can be increased when it is combined with Nelfinavir. Approved, Investigational Metronidazole The metabolism of Metronidazole can be decreased when combined with Nelfinavir. Approved Mexiletine The metabolism of Mexiletine can be decreased when combined with Nelfinavir. Approved Mianserin The metabolism of Mianserin can be decreased when combined with Nelfinavir. Approved Mibefradil The metabolism of Mibefradil can be decreased when combined with Nelfinavir. Withdrawn Miconazole The metabolism of Miconazole can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Midazolam The serum concentration of Midazolam can be increased when it is combined with Nelfinavir. Approved, Illicit Mifepristone Mifepristone may increase the QTc-prolonging activities of Nelfinavir. Approved, Investigational Miglitol The therapeutic efficacy of Miglitol can be decreased when used in combination with Nelfinavir. Approved Miglustat The therapeutic efficacy of Miglustat can be decreased when used in combination with Nelfinavir. Approved Mirabegron The metabolism of Mirabegron can be decreased when combined with Nelfinavir. Approved Mirtazapine The metabolism of Mirtazapine can be decreased when combined with Nelfinavir. Approved Mitiglinide The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Nelfinavir. Approved, Investigational Mitomycin The serum concentration of Nelfinavir can be increased when it is combined with Mitomycin. Approved Mitotane The serum concentration of Nelfinavir can be decreased when it is combined with Mitotane. Approved Mitoxantrone The serum concentration of Mitoxantrone can be decreased when it is combined with Nelfinavir. Approved, Investigational Moclobemide The metabolism of Moclobemide can be decreased when combined with Nelfinavir. Approved Modafinil The metabolism of Modafinil can be decreased when combined with Nelfinavir. Approved, Investigational Mometasone The serum concentration of Mometasone can be increased when it is combined with Nelfinavir. Approved, Vet Approved Montelukast The metabolism of Montelukast can be decreased when combined with Nelfinavir. Approved Morphine The metabolism of Morphine can be decreased when combined with Nelfinavir. Approved, Investigational Moxifloxacin Nelfinavir may increase the QTc-prolonging activities of Moxifloxacin. Approved, Investigational Mycophenolate mofetil The metabolism of Mycophenolate mofetil can be decreased when combined with Nelfinavir. Approved, Investigational Nadolol The serum concentration of Nadolol can be decreased when it is combined with Nelfinavir. Approved Nafcillin The serum concentration of Nelfinavir can be decreased when it is combined with Nafcillin. Approved Naloxegol The serum concentration of Naloxegol can be increased when it is combined with Nelfinavir. Approved Naloxone The metabolism of Naloxone can be decreased when combined with Nelfinavir. Approved, Vet Approved Naltrexone The serum concentration of Nelfinavir can be increased when it is combined with Naltrexone. Approved, Investigational, Vet Approved Naringenin The serum concentration of Nelfinavir can be increased when it is combined with Naringenin. Experimental Nateglinide The metabolism of Nateglinide can be decreased when combined with Nelfinavir. Approved, Investigational NCX 1022 The serum concentration of NCX 1022 can be increased when it is combined with Nelfinavir. Investigational Nefazodone The serum concentration of Nefazodone can be increased when it is combined with Nelfinavir. Approved, Withdrawn Neostigmine The serum concentration of Nelfinavir can be increased when it is combined with Neostigmine. Approved, Vet Approved Netupitant The serum concentration of Nelfinavir can be increased when it is combined with Netupitant. Approved Nevirapine The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Nevirapine resulting in a loss in efficacy. Approved Nicardipine The metabolism of Nicardipine can be decreased when combined with Nelfinavir. Approved Nicotine The metabolism of Nicotine can be decreased when combined with Nelfinavir. Approved Nifedipine The metabolism of Nifedipine can be decreased when combined with Nelfinavir. Approved Nilotinib The serum concentration of Nilotinib can be increased when it is combined with Nelfinavir. Approved, Investigational Nilutamide The metabolism of Nilutamide can be decreased when combined with Nelfinavir. Approved Nilvadipine The metabolism of Nilvadipine can be decreased when combined with Nelfinavir. Approved Nimodipine The serum concentration of Nimodipine can be increased when it is combined with Nelfinavir. Approved Nintedanib The serum concentration of Nintedanib can be increased when it is combined with Nelfinavir. Approved Nisoldipine The serum concentration of Nisoldipine can be increased when it is combined with Nelfinavir. Approved Nitrazepam The metabolism of Nitrazepam can be decreased when combined with Nelfinavir. Approved Nitrendipine The metabolism of Nitrendipine can be decreased when combined with Nelfinavir. Approved Nizatidine The serum concentration of Nelfinavir can be decreased when it is combined with Nizatidine. Approved Norelgestromin The serum concentration of Norelgestromin can be decreased when it is combined with Nelfinavir. Approved Norethisterone The metabolism of Norethisterone can be decreased when combined with Nelfinavir. Approved Norgestimate The serum concentration of Norgestimate can be decreased when it is combined with Nelfinavir. Approved Norgestrel The serum concentration of Norgestrel can be decreased when it is combined with Nelfinavir. Approved Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Nelfinavir. Approved Ofloxacin Nelfinavir may increase the QTc-prolonging activities of Ofloxacin. Approved Olanzapine The serum concentration of Nelfinavir can be decreased when it is combined with Olanzapine. Approved, Investigational Olaparib The serum concentration of Olaparib can be increased when it is combined with Nelfinavir. Approved Oleoyl-estrone The serum concentration of Oleoyl estrone can be increased when it is combined with Nelfinavir. Investigational Olopatadine The metabolism of Olopatadine can be decreased when combined with Nelfinavir. Approved Ombitasvir The serum concentration of Ombitasvir can be decreased when it is combined with Nelfinavir. Approved Omeprazole The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Omeprazole resulting in a loss in efficacy. Approved, Investigational, Vet Approved Ondansetron The metabolism of Ondansetron can be decreased when combined with Nelfinavir. Approved Opipramol The serum concentration of Opipramol can be increased when it is combined with Nelfinavir. Investigational Orphenadrine The metabolism of Orphenadrine can be decreased when combined with Nelfinavir. Approved Osimertinib The serum concentration of Osimertinib can be increased when it is combined with Nelfinavir. Approved Ospemifene The serum concentration of Ospemifene can be increased when it is combined with Nelfinavir. Approved Oxazepam The metabolism of Oxazepam can be decreased when combined with Nelfinavir. Approved Oxiconazole The metabolism of Oxiconazole can be decreased when combined with Nelfinavir. Approved Oxybutynin The serum concentration of Oxybutynin can be increased when it is combined with Nelfinavir. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Nelfinavir is combined with Oxycodone. Approved, Illicit, Investigational Oxymorphone The metabolism of Oxymorphone can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved P-Nitrophenol The serum concentration of Nelfinavir can be increased when it is combined with P-Nitrophenol. Experimental Paclitaxel The metabolism of Paclitaxel can be decreased when combined with Nelfinavir. Approved, Vet Approved Palbociclib The serum concentration of Palbociclib can be increased when it is combined with Nelfinavir. Approved Paliperidone Nelfinavir may increase the QTc-prolonging activities of Paliperidone. Approved Palmitic Acid The serum concentration of Nelfinavir can be increased when it is combined with Palmitic Acid. Experimental Palonosetron The metabolism of Palonosetron can be decreased when combined with Nelfinavir. Approved, Investigational Panobinostat The serum concentration of Panobinostat can be increased when it is combined with Nelfinavir. Approved, Investigational Pantoprazole The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Pantoprazole resulting in a loss in efficacy. Approved Paramethadione The metabolism of Paramethadione can be decreased when combined with Nelfinavir. Approved Paramethasone The metabolism of Paramethasone can be decreased when combined with Nelfinavir. Approved Parecoxib The serum concentration of Parecoxib can be increased when it is combined with Nelfinavir. Approved Paricalcitol The serum concentration of Paricalcitol can be increased when it is combined with Nelfinavir. Approved, Investigational Paritaprevir The metabolism of Paritaprevir can be decreased when combined with Nelfinavir. Approved Paroxetine The serum concentration of Nelfinavir can be increased when it is combined with Paroxetine. Approved, Investigational Pazopanib The serum concentration of Pazopanib can be increased when it is combined with Nelfinavir. Approved Pentamidine The metabolism of Pentamidine can be decreased when combined with Nelfinavir. Approved Pentobarbital The metabolism of Nelfinavir can be increased when combined with Pentobarbital. Approved, Vet Approved Perampanel The metabolism of Perampanel can be decreased when combined with Nelfinavir. Approved Perflutren Nelfinavir may increase the QTc-prolonging activities of Perflutren. Approved Pergolide The metabolism of Pergolide can be decreased when combined with Nelfinavir. Approved, Vet Approved, Withdrawn Perhexiline The metabolism of Perhexiline can be decreased when combined with Nelfinavir. Approved Perindopril The serum concentration of Nelfinavir can be increased when it is combined with Perindopril. Approved Permethrin The metabolism of Permethrin can be decreased when combined with Nelfinavir. Approved, Investigational Perphenazine The metabolism of Perphenazine can be decreased when combined with Nelfinavir. Approved Pethidine The risk or severity of adverse effects can be increased when Nelfinavir is combined with Pethidine. Approved Phenacetin The metabolism of Phenacetin can be decreased when combined with Nelfinavir. Withdrawn Phenformin The therapeutic efficacy of Phenformin can be decreased when used in combination with Nelfinavir. Approved, Withdrawn Phenobarbital The metabolism of Nelfinavir can be increased when combined with Phenobarbital. Approved Phenoxybenzamine The metabolism of Phenoxybenzamine can be decreased when combined with Nelfinavir. Approved Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Nelfinavir. Approved Phenytoin The serum concentration of Phenytoin can be decreased when it is combined with Nelfinavir. Approved, Vet Approved Pilocarpine The metabolism of Pilocarpine can be decreased when combined with Nelfinavir. Approved Pimecrolimus The metabolism of Pimecrolimus can be decreased when combined with Nelfinavir. Approved, Investigational Pimozide The serum concentration of Pimozide can be increased when it is combined with Nelfinavir. Approved Pinacidil The metabolism of Pinacidil can be decreased when combined with Nelfinavir. Withdrawn Pioglitazone The metabolism of Pioglitazone can be decreased when combined with Nelfinavir. Approved, Investigational Pipotiazine The metabolism of Pipotiazine can be decreased when combined with Nelfinavir. Approved Pitavastatin The serum concentration of Pitavastatin can be decreased when it is combined with Nelfinavir. Approved Platelet Activating Factor The serum concentration of Nelfinavir can be decreased when it is combined with Platelet Activating Factor. Experimental Podofilox The metabolism of Podofilox can be decreased when combined with Nelfinavir. Approved Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Nelfinavir. Approved Ponatinib The serum concentration of Ponatinib can be increased when it is combined with Nelfinavir. Approved Posaconazole The metabolism of Posaconazole can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Pramlintide The therapeutic efficacy of Pramlintide can be decreased when used in combination with Nelfinavir. Approved, Investigational Pranlukast The serum concentration of Pranlukast can be increased when it is combined with Nelfinavir. Approved Prasterone The metabolism of Prasterone can be decreased when combined with Nelfinavir. Approved, Nutraceutical Prasterone sulfate The serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Nelfinavir. Investigational Prasugrel The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Nelfinavir resulting in a loss in efficacy. Approved Pravastatin The serum concentration of Pravastatin can be decreased when it is combined with Nelfinavir. Approved Prazepam The metabolism of Prazepam can be decreased when combined with Nelfinavir. Approved, Illicit Praziquantel The metabolism of Praziquantel can be decreased when combined with Nelfinavir. Approved, Vet Approved Prazosin The serum concentration of Prazosin can be decreased when it is combined with Nelfinavir. Approved Prednicarbate The serum concentration of Prednicarbate can be increased when it is combined with Nelfinavir. Approved Prednisolone The metabolism of Prednisolone can be decreased when combined with Nelfinavir. Approved, Vet Approved Prednisolone The serum concentration of Prednisolone can be increased when it is combined with Nelfinavir. Approved, Vet Approved Prednisone The serum concentration of Prednisone can be increased when it is combined with Nelfinavir. Approved, Vet Approved Pregnenolone The serum concentration of Pregnenolone can be increased when it is combined with Nelfinavir. Experimental Primaquine The metabolism of Primaquine can be decreased when combined with Nelfinavir. Approved Primidone The metabolism of Nelfinavir can be increased when combined with Primidone. Approved, Vet Approved Probenecid The serum concentration of Nelfinavir can be increased when it is combined with Probenecid. Approved Procainamide Nelfinavir may increase the QTc-prolonging activities of Procainamide. Approved Prochlorperazine The metabolism of Prochlorperazine can be decreased when combined with Nelfinavir. Approved, Vet Approved Progesterone The metabolism of Progesterone can be decreased when combined with Nelfinavir. Approved, Vet Approved Proguanil The metabolism of Proguanil can be decreased when combined with Nelfinavir. Approved Promazine The metabolism of Promazine can be decreased when combined with Nelfinavir. Approved, Vet Approved Promethazine The serum concentration of Nelfinavir can be increased when it is combined with Promethazine. Approved Propafenone The serum concentration of Propafenone can be increased when it is combined with Nelfinavir. Approved Propofol The metabolism of Propofol can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Propranolol The metabolism of Propranolol can be decreased when combined with Nelfinavir. Approved, Investigational Protriptyline The serum concentration of Protriptyline can be increased when it is combined with Nelfinavir. Approved Prucalopride The serum concentration of Prucalopride can be increased when it is combined with Nelfinavir. Approved Pyrazinamide The metabolism of Pyrazinamide can be decreased when combined with Nelfinavir. Approved Quazepam The metabolism of Quazepam can be decreased when combined with Nelfinavir. Approved, Illicit Quercetin The serum concentration of Nelfinavir can be increased when it is combined with Quercetin. Experimental Quetiapine The serum concentration of Quetiapine can be increased when it is combined with Nelfinavir. Approved Quinacrine The metabolism of Quinacrine can be decreased when combined with Nelfinavir. Approved Quinidine The serum concentration of Quinidine can be increased when it is combined with Nelfinavir. Approved Quinine The metabolism of Quinine can be decreased when combined with Nelfinavir. Approved Rabeprazole The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Rabeprazole resulting in a loss in efficacy. Approved, Investigational Raloxifene The metabolism of Raloxifene can be decreased when combined with Nelfinavir. Approved, Investigational Ramelteon The serum concentration of Ramelteon can be increased when it is combined with Nelfinavir. Approved, Investigational Ranitidine The serum concentration of Nelfinavir can be decreased when it is combined with Ranitidine. Approved Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Nelfinavir. Approved, Investigational Reboxetine The metabolism of Reboxetine can be decreased when combined with Nelfinavir. Approved, Investigational Regorafenib The serum concentration of Regorafenib can be increased when it is combined with Nelfinavir. Approved Repaglinide The serum concentration of Repaglinide can be increased when it is combined with Nelfinavir. Approved, Investigational Reserpine The serum concentration of Reserpine can be decreased when it is combined with Nelfinavir. Approved Retapamulin The serum concentration of Retapamulin can be increased when it is combined with Nelfinavir. Approved Rifabutin The serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Nelfinavir. Approved Rifampicin The serum concentration of Nelfinavir can be decreased when it is combined with Rifampicin. Approved Rifapentine The metabolism of Nelfinavir can be increased when combined with Rifapentine. Approved Rifaximin The serum concentration of Rifaximin can be increased when it is combined with Nelfinavir. Approved, Investigational Rilpivirine The serum concentration of Rilpivirine can be increased when it is combined with Nelfinavir. Approved Rimexolone The serum concentration of Rimexolone can be increased when it is combined with Nelfinavir. Approved Rimonabant The metabolism of Rimonabant can be decreased when combined with Nelfinavir. Approved, Investigational Riociguat The serum concentration of Riociguat can be increased when it is combined with Nelfinavir. Approved Risperidone The metabolism of Risperidone can be decreased when combined with Nelfinavir. Approved, Investigational Ritonavir The metabolism of Ritonavir can be decreased when combined with Nelfinavir. Approved, Investigational Rivaroxaban The metabolism of Rivaroxaban can be decreased when combined with Nelfinavir. Approved Rofecoxib The metabolism of Rofecoxib can be decreased when combined with Nelfinavir. Investigational, Withdrawn Rolapitant The metabolism of Rolapitant can be decreased when combined with Nelfinavir. Approved Romidepsin The serum concentration of Romidepsin can be increased when it is combined with Nelfinavir. Approved, Investigational Ropinirole The metabolism of Ropinirole can be decreased when combined with Nelfinavir. Approved, Investigational Ropivacaine The metabolism of Ropivacaine can be decreased when combined with Nelfinavir. Approved Rosiglitazone The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Nelfinavir. Approved, Investigational Rosuvastatin The serum concentration of Rosuvastatin can be increased when it is combined with Nelfinavir. Approved Rotigotine The metabolism of Rotigotine can be decreased when combined with Nelfinavir. Approved Roxatidine acetate The serum concentration of Nelfinavir can be decreased when it is combined with Roxatidine acetate. Approved Roxithromycin The metabolism of Roxithromycin can be decreased when combined with Nelfinavir. Approved, Withdrawn Ruxolitinib The serum concentration of Ruxolitinib can be increased when it is combined with Nelfinavir. Approved Salicylic acid The serum concentration of Salicylic acid can be decreased when it is combined with Nelfinavir. Approved, Vet Approved Salmeterol The serum concentration of Salmeterol can be increased when it is combined with Nelfinavir. Approved Saquinavir The metabolism of Saquinavir can be decreased when combined with Nelfinavir. Approved, Investigational Saxagliptin The serum concentration of Saxagliptin can be increased when it is combined with Nelfinavir. Approved Scopolamine The serum concentration of Nelfinavir can be increased when it is combined with Scopolamine. Approved Selegiline The metabolism of Selegiline can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Selexipag The metabolism of Selexipag can be decreased when combined with Nelfinavir. Approved Seratrodast The metabolism of Seratrodast can be decreased when combined with Nelfinavir. Approved Sertindole The metabolism of Sertindole can be decreased when combined with Nelfinavir. Approved, Withdrawn Sertraline The metabolism of Sertraline can be decreased when combined with Nelfinavir. Approved Sevoflurane The metabolism of Sevoflurane can be decreased when combined with Nelfinavir. Approved, Vet Approved Sibutramine The metabolism of Sibutramine can be decreased when combined with Nelfinavir. Approved, Illicit, Investigational, Withdrawn Sildenafil The serum concentration of Sildenafil can be increased when it is combined with Nelfinavir. Approved, Investigational Silodosin The serum concentration of Silodosin can be increased when it is combined with Nelfinavir. Approved Siltuximab The serum concentration of Nelfinavir can be decreased when it is combined with Siltuximab. Approved Simeprevir The serum concentration of Simeprevir can be increased when it is combined with Nelfinavir. Approved Simvastatin The serum concentration of Simvastatin can be increased when it is combined with Nelfinavir. Approved Sirolimus The serum concentration of Sirolimus can be increased when it is combined with Nelfinavir. Approved, Investigational Sitagliptin The metabolism of Sitagliptin can be decreased when combined with Nelfinavir. Approved, Investigational Sofosbuvir The serum concentration of Sofosbuvir can be decreased when it is combined with Nelfinavir. Approved Solifenacin The metabolism of Solifenacin can be decreased when combined with Nelfinavir. Approved Sonidegib The serum concentration of Sonidegib can be increased when it is combined with Nelfinavir. Approved, Investigational Sorafenib The serum concentration of Sorafenib can be increased when it is combined with Nelfinavir. Approved, Investigational Sotalol Nelfinavir may increase the QTc-prolonging activities of Sotalol. Approved Sparfloxacin The serum concentration of Sparfloxacin can be decreased when it is combined with Nelfinavir. Approved Sphingosine The serum concentration of Sphingosine can be decreased when it is combined with Nelfinavir. Experimental Spiramycin The metabolism of Spiramycin can be decreased when combined with Nelfinavir. Approved Spironolactone The serum concentration of Nelfinavir can be increased when it is combined with Spironolactone. Approved St. John's Wort The metabolism of Nelfinavir can be increased when combined with St. John's Wort. Nutraceutical Staurosporine The serum concentration of Nelfinavir can be increased when it is combined with Staurosporine. Experimental Stiripentol The serum concentration of Nelfinavir can be increased when it is combined with Stiripentol. Approved Streptozocin The serum concentration of Nelfinavir can be decreased when it is combined with Streptozocin. Approved Sufentanil The metabolism of Sufentanil can be decreased when combined with Nelfinavir. Approved, Investigational Sulfadiazine The metabolism of Sulfadiazine can be decreased when combined with Nelfinavir. Approved, Vet Approved Sulfamethoxazole The metabolism of Sulfamethoxazole can be decreased when combined with Nelfinavir. Approved Sulfinpyrazone The metabolism of Sulfinpyrazone can be decreased when combined with Nelfinavir. Approved Sulfisoxazole Nelfinavir may increase the QTc-prolonging activities of Sulfisoxazole. Approved, Vet Approved Sulodexide The therapeutic efficacy of Sulodexide can be decreased when used in combination with Nelfinavir. Approved, Investigational Sumatriptan The serum concentration of Nelfinavir can be increased when it is combined with Sumatriptan. Approved, Investigational Sunitinib The metabolism of Sunitinib can be decreased when combined with Nelfinavir. Approved, Investigational Suvorexant The serum concentration of Suvorexant can be increased when it is combined with Nelfinavir. Approved Synthetic Conjugated Estrogens, A The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Nelfinavir. Approved Synthetic Conjugated Estrogens, B The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Nelfinavir. Approved Tacrine The serum concentration of Nelfinavir can be increased when it is combined with Tacrine. Withdrawn Tacrolimus The metabolism of Tacrolimus can be decreased when combined with Nelfinavir. Approved, Investigational Tadalafil The serum concentration of Tadalafil can be increased when it is combined with Nelfinavir. Approved, Investigational Tamoxifen The metabolism of Tamoxifen can be decreased when combined with Nelfinavir. Approved Tamsulosin The serum concentration of Tamsulosin can be increased when it is combined with Nelfinavir. Approved, Investigational Tapentadol The metabolism of Tapentadol can be decreased when combined with Nelfinavir. Approved Tasimelteon The serum concentration of Tasimelteon can be increased when it is combined with Nelfinavir. Approved Tasosartan The metabolism of Tasosartan can be decreased when combined with Nelfinavir. Approved Taurochenodeoxycholic acid The metabolism of Taurochenodeoxycholic acid can be decreased when combined with Nelfinavir. Experimental Taurocholic Acid The serum concentration of Taurocholic Acid can be decreased when it is combined with Nelfinavir. Experimental Technetium Tc-99m sestamibi The serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Nelfinavir. Approved Telaprevir The metabolism of Telaprevir can be decreased when combined with Nelfinavir. Withdrawn Telavancin Nelfinavir may increase the QTc-prolonging activities of Telavancin. Approved Telithromycin The metabolism of Telithromycin can be decreased when combined with Nelfinavir. Approved Telmisartan The serum concentration of Nelfinavir can be increased when it is combined with Telmisartan. Approved, Investigational Temazepam The metabolism of Temazepam can be decreased when combined with Nelfinavir. Approved Temsirolimus The risk or severity of adverse effects can be increased when Nelfinavir is combined with Temsirolimus. Approved Teniposide The metabolism of Teniposide can be decreased when combined with Nelfinavir. Approved Terazosin The serum concentration of Nelfinavir can be increased when it is combined with Terazosin. Approved Terbinafine The metabolism of Terbinafine can be decreased when combined with Nelfinavir. Approved, Investigational, Vet Approved Terfenadine The serum concentration of Terfenadine can be increased when it is combined with Nelfinavir. Withdrawn Tesmilifene The metabolism of Tesmilifene can be decreased when combined with Nelfinavir. Investigational Testosterone The metabolism of Testosterone can be decreased when combined with Nelfinavir. Approved, Investigational Tetrabenazine Nelfinavir may increase the QTc-prolonging activities of Tetrabenazine. Approved Tetracycline The metabolism of Tetracycline can be decreased when combined with Nelfinavir. Approved, Vet Approved Thalidomide The metabolism of Thalidomide can be decreased when combined with Nelfinavir. Approved, Investigational, Withdrawn Theophylline The metabolism of Theophylline can be decreased when combined with Nelfinavir. Approved Thioridazine The serum concentration of Thioridazine can be increased when it is combined with Nelfinavir. Withdrawn Thiotepa The metabolism of Thiotepa can be decreased when combined with Nelfinavir. Approved Tiagabine The metabolism of Tiagabine can be decreased when combined with Nelfinavir. Approved Tianeptine The serum concentration of Tianeptine can be increased when it is combined with Nelfinavir. Approved Ticagrelor The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Nelfinavir resulting in a loss in efficacy. Approved Ticlopidine The metabolism of Ticlopidine can be decreased when combined with Nelfinavir. Approved Timolol The serum concentration of Timolol can be decreased when it is combined with Nelfinavir. Approved Tinidazole The metabolism of Tinidazole can be decreased when combined with Nelfinavir. Approved, Investigational Tiotropium The metabolism of Tiotropium can be decreased when combined with Nelfinavir. Approved Tipranavir The serum concentration of Nelfinavir can be decreased when it is combined with Tipranavir. Approved, Investigational Tixocortol The serum concentration of Tixocortol can be increased when it is combined with Nelfinavir. Approved Tizanidine The serum concentration of Tizanidine can be increased when it is combined with Nelfinavir. Approved Tocilizumab The serum concentration of Nelfinavir can be decreased when it is combined with Tocilizumab. Approved Tofacitinib The serum concentration of Tofacitinib can be increased when it is combined with Nelfinavir. Approved, Investigational Tolazamide The therapeutic efficacy of Tolazamide can be decreased when used in combination with Nelfinavir. Approved Tolbutamide The metabolism of Tolbutamide can be decreased when combined with Nelfinavir. Approved Tolterodine The serum concentration of Tolterodine can be increased when it is combined with Nelfinavir. Approved, Investigational Tolvaptan The serum concentration of Tolvaptan can be increased when it is combined with Nelfinavir. Approved Topiramate The metabolism of Nelfinavir can be decreased when combined with Topiramate. Approved Topotecan The serum concentration of Topotecan can be increased when it is combined with Nelfinavir. Approved, Investigational Toremifene The risk or severity of adverse effects can be increased when Nelfinavir is combined with Toremifene. Approved, Investigational Trabectedin The serum concentration of Trabectedin can be increased when it is combined with Nelfinavir. Approved, Investigational Tramadol The serum concentration of Tramadol can be increased when it is combined with Nelfinavir. Approved, Investigational Tranylcypromine The metabolism of Nelfinavir can be decreased when combined with Tranylcypromine. Approved Trastuzumab emtansine The serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Nelfinavir. Approved Trazodone The serum concentration of Trazodone can be increased when it is combined with Nelfinavir. Approved, Investigational Tretinoin The metabolism of Tretinoin can be decreased when combined with Nelfinavir. Approved, Investigational, Nutraceutical Triamcinolone The metabolism of Triamcinolone can be decreased when combined with Nelfinavir. Approved, Vet Approved Triazolam The serum concentration of Triazolam can be increased when it is combined with Nelfinavir. Approved Trifluoperazine The serum concentration of Nelfinavir can be increased when it is combined with Trifluoperazine. Approved Triflupromazine The serum concentration of Nelfinavir can be increased when it is combined with Triflupromazine. Approved, Vet Approved Trimethadione The metabolism of Trimethadione can be decreased when combined with Nelfinavir. Approved Trimethoprim The metabolism of Trimethoprim can be decreased when combined with Nelfinavir. Approved, Vet Approved Trimipramine The metabolism of Trimipramine can be decreased when combined with Nelfinavir. Approved Troglitazone The metabolism of Troglitazone can be decreased when combined with Nelfinavir. Withdrawn Udenafil The metabolism of Udenafil can be decreased when combined with Nelfinavir. Approved, Investigational Ulipristal The serum concentration of Ulipristal can be increased when it is combined with Nelfinavir. Approved Umeclidinium The serum concentration of Umeclidinium can be decreased when it is combined with Nelfinavir. Approved Valdecoxib The metabolism of Valdecoxib can be decreased when combined with Nelfinavir. Investigational, Withdrawn Valproic Acid The serum concentration of Valproic Acid can be decreased when it is combined with Nelfinavir. Approved, Investigational Vandetanib The metabolism of Vandetanib can be decreased when combined with Nelfinavir. Approved Vanoxerine The metabolism of Vanoxerine can be decreased when combined with Nelfinavir. Investigational Vardenafil The serum concentration of Vardenafil can be increased when it is combined with Nelfinavir. Approved Vecuronium The serum concentration of Vecuronium can be decreased when it is combined with Nelfinavir. Approved Vemurafenib The serum concentration of Vemurafenib can be increased when it is combined with Nelfinavir. Approved Venetoclax The metabolism of Venetoclax can be decreased when combined with Nelfinavir. Approved Venlafaxine The metabolism of Venlafaxine can be decreased when combined with Nelfinavir. Approved Verapamil The metabolism of Verapamil can be decreased when combined with Nelfinavir. Approved Vicriviroc The metabolism of Vicriviroc can be decreased when combined with Nelfinavir. Investigational Vilanterol The metabolism of Vilanterol can be decreased when combined with Nelfinavir. Approved Vilazodone The serum concentration of Vilazodone can be increased when it is combined with Nelfinavir. Approved Vildagliptin The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Nelfinavir. Approved, Investigational Vinblastine The metabolism of Vinblastine can be decreased when combined with Nelfinavir. Approved Vincristine The serum concentration of Vincristine can be increased when it is combined with Nelfinavir. Approved, Investigational Vincristine The metabolism of Vincristine can be decreased when combined with Nelfinavir. Approved, Investigational Vindesine The serum concentration of Vindesine can be increased when it is combined with Nelfinavir. Approved Vinorelbine The metabolism of Vinorelbine can be decreased when combined with Nelfinavir. Approved, Investigational Vismodegib The metabolism of Vismodegib can be decreased when combined with Nelfinavir. Approved Voglibose The therapeutic efficacy of Voglibose can be decreased when used in combination with Nelfinavir. Approved, Investigational Vorapaxar The serum concentration of Vorapaxar can be increased when it is combined with Nelfinavir. Approved Voriconazole The serum concentration of Nelfinavir can be increased when it is combined with Voriconazole. Approved, Investigational Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Nelfinavir. Approved Warfarin The serum concentration of Warfarin can be decreased when it is combined with Nelfinavir. Approved Yohimbine The metabolism of Yohimbine can be decreased when combined with Nelfinavir. Approved, Vet Approved Zafirlukast The metabolism of Zafirlukast can be decreased when combined with Nelfinavir. Approved, Investigational Zalcitabine The metabolism of Zalcitabine can be decreased when combined with Nelfinavir. Approved Zaleplon The metabolism of Zaleplon can be decreased when combined with Nelfinavir. Approved, Illicit, Investigational Zidovudine The serum concentration of Zidovudine can be decreased when it is combined with Nelfinavir. Approved Zileuton The metabolism of Zileuton can be decreased when combined with Nelfinavir. Approved, Investigational, Withdrawn Zimelidine The serum concentration of Nelfinavir can be increased when it is combined with Zimelidine. Withdrawn Ziprasidone The metabolism of Ziprasidone can be decreased when combined with Nelfinavir. Approved Zolpidem The metabolism of Zolpidem can be decreased when combined with Nelfinavir. Approved Zomepirac The metabolism of Zomepirac can be decreased when combined with Nelfinavir. Withdrawn Zonisamide The metabolism of Zonisamide can be decreased when combined with Nelfinavir. Approved, Investigational Zopiclone The serum concentration of Zopiclone can be increased when it is combined with Nelfinavir. Approved Zuclopenthixol The serum concentration of Zuclopenthixol can be increased when it is combined with Nelfinavir. Approved, Investigational - Food Interactions
- Food significantly increases absorption (2 to 3 times).
- Take with food.
References
- Synthesis Reference
- US5461154
- General References
- Kaldor SW, Kalish VJ, Davies JF 2nd, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS, Tatlock JH: Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem. 1997 Nov 21;40(24):3979-85. [PubMed:9397180 ]
- External Links
- Human Metabolome Database
- HMDB14365
- KEGG Drug
- D08259
- KEGG Compound
- C07257
- PubChem Compound
- 64143
- PubChem Substance
- 46507719
- ChemSpider
- 57718
- BindingDB
- 518
- ChEBI
- 7496
- ChEMBL
- CHEMBL584
- Therapeutic Targets Database
- DAP000705
- PharmGKB
- PA450606
- HET
- 1UN
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Nelfinavir
- ATC Codes
- J05AE04 — Nelfinavir
- AHFS Codes
- 08:18.08.08
- PDB Entries
- FDA label
- Download (294 KB)
- MSDS
- Download (56.6 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Agouron pharmaceuticals inc
- Packagers
- Agouron Pharmaceuticals Inc.
- A-S Medication Solutions LLC
- Cardinal Health
- Dept Health Central Pharmacy
- Dispensing Solutions
- Goedecke GmbH
- H.J. Harkins Co. Inc.
- Kaiser Foundation Hospital
- Lake Erie Medical and Surgical Supply
- Patheon Inc.
- PD-Rx Pharmaceuticals Inc.
- Pfizer Inc.
- Physicians Total Care Inc.
- Quality Care
- Remedy Repack
- St Mary's Medical Park Pharmacy
- Watson Pharmaceuticals
- Dosage forms
Form Route Strength Powder Oral 50 mg/g Tablet Oral 625 mg Tablet, film coated Oral 250 mg/1 Tablet, film coated Oral 625 mg/1 Tablet Oral 250 mg Powder Oral 50 mg - Prices
Unit description Cost Unit Viracept 625 mg tablet 11.24USD tablet Viracept 250 mg tablet 3.46USD tablet Viracept 50 mg/gm Powder 0.54USD gm DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5484926 No 1994-04-07 2014-04-07 US CA2173328 No 1999-08-31 2014-10-07 Canada
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 349.84 °C Not Available water solubility Slightly soluble Not Available logP 6 Not Available - Predicted Properties
Property Value Source Water Solubility 0.00191 mg/mL ALOGPS logP 4.61 ALOGPS logP 4.72 ChemAxon logS -5.5 ALOGPS pKa (Strongest Acidic) 9.32 ChemAxon pKa (Strongest Basic) 8.18 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 101.9 Å2 ChemAxon Rotatable Bond Count 10 ChemAxon Refractivity 162.67 m3·mol-1 ChemAxon Polarizability 63.8 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.7472 Blood Brain Barrier - 0.9659 Caco-2 permeable - 0.7148 P-glycoprotein substrate Substrate 0.9332 P-glycoprotein inhibitor I Inhibitor 0.8121 P-glycoprotein inhibitor II Inhibitor 0.7572 Renal organic cation transporter Non-inhibitor 0.8178 CYP450 2C9 substrate Non-substrate 0.7482 CYP450 2D6 substrate Substrate 0.8918 CYP450 3A4 substrate Substrate 0.7408 CYP450 1A2 substrate Non-inhibitor 0.9085 CYP450 2C9 inhibitor Non-inhibitor 0.7994 CYP450 2D6 inhibitor Non-inhibitor 0.8071 CYP450 2C19 inhibitor Non-inhibitor 0.6335 CYP450 3A4 inhibitor Inhibitor 0.5465 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8977 Ames test Non AMES toxic 0.8008 Carcinogenicity Non-carcinogens 0.8547 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.4704 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9786 hERG inhibition (predictor II) Inhibitor 0.785
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted LC-MS/MS Spectrum - 10V, Positive Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 20V, Positive Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 40V, Positive Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 10V, Negative Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 20V, Negative Predicted LC-MS/MS Not Available Predicted LC-MS/MS Spectrum - 40V, Negative Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acid amides
- Alternative Parents
- o-Toluamides / Piperidinecarboxamides / Benzamides / Thiophenol ethers / Ortho cresols / Benzoyl derivatives / 1-hydroxy-2-unsubstituted benzenoids / 1-hydroxy-4-unsubstituted benzenoids / Alkylarylthioethers / Trialkylamines show 9 more
- Substituents
- Alpha-amino acid amide / Piperidinecarboxamide / 2-piperidinecarboxamide / Toluamide / Benzamide / O-toluamide / Benzoic acid or derivatives / Thiophenol ether / O-cresol / Benzoyl show 31 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- tertiary amino compound, secondary alcohol, aryl sulfide, phenols, benzamides, organic heterobicyclic compound (CHEBI:7496 )
Targets
- Kind
- Protein
- Organism
- Human immunodeficiency virus
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Aspartic-type endopeptidase activity
- Specific Function
- Not Available
- Gene Name
- HIV-1 protease
- Uniprot ID
- O90777
- Uniprot Name
- HIV-1 protease
- Molecular Weight
- 10724.61 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
- Garriga C, Perez-Elias MJ, Delgado R, Ruiz L, Najera R, Pumarola T, Alonso-Socas Mdel M, Garcia-Bujalance S, Menendez-Arias L: Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. J Med Virol. 2007 Nov;79(11):1617-28. [PubMed:17854027 ]
- Wittayanarakul K, Hannongbua S, Feig M: Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors. J Comput Chem. 2008 Apr 15;29(5):673-85. [PubMed:17849388 ]
- Dandache S, Sevigny G, Yelle J, Stranix BR, Parkin N, Schapiro JM, Wainberg MA, Wu JJ: In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007 Nov;51(11):4036-43. Epub 2007 Jul 16. [PubMed:17638694 ]
- Perez MA, Fernandes PA, Ramos MJ: Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead. J Mol Graph Model. 2007 Oct;26(3):634-42. Epub 2007 Mar 24. [PubMed:17459746 ]
- Velazquez-Campoy A, Kiso Y, Freire E: The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. Arch Biochem Biophys. 2001 Jun 15;390(2):169-75. [PubMed:11396919 ]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
- Gene Name
- CYP2C19
- Uniprot ID
- P33261
- Uniprot Name
- Cytochrome P450 2C19
- Molecular Weight
- 55930.545 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2B6
- Uniprot ID
- P20813
- Uniprot Name
- Cytochrome P450 2B6
- Molecular Weight
- 56277.81 Da
References
- Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ: Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos. 2001 Feb;29(2):100-2. [PubMed:11159797 ]
- Tanabe M, Hashimoto M, Ono H: Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. Eur J Pharmacol. 2008 Jul 28;589(1-3):102-5. doi: 10.1016/j.ejphar.2008.06.013. Epub 2008 Jun 7. [PubMed:18602099 ]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A7
- Uniprot ID
- P24462
- Uniprot Name
- Cytochrome P450 3A7
- Molecular Weight
- 57525.03 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
- Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C9
- Uniprot ID
- P11712
- Uniprot Name
- Cytochrome P450 2C9
- Molecular Weight
- 55627.365 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Bocedi A, Notaril S, Narciso P, Bolli A, Fasano M, Ascenzi P: Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. [PubMed:15814459 ]
- Bocedi A, Notari S, Menegatti E, Fanali G, Fasano M, Ascenzi P: Allosteric modulation of anti-HIV drug and ferric heme binding to human serum albumin. FEBS J. 2005 Dec;272(24):6287-96. [PubMed:16336266 ]
Transporters
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitorInducer
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ: Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000 Jun 16;14(9):1287-9. [PubMed:10894301 ]
- Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. [PubMed:10820137 ]
- Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
- Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998 Jan 15;101(2):289-94. [PubMed:9435299 ]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Secondary active organic cation transmembrane transporter activity
- Specific Function
- Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnico...
- Gene Name
- SLC22A1
- Uniprot ID
- O15245
- Uniprot Name
- Solute carrier family 22 member 1
- Molecular Weight
- 61153.345 Da
References
- Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, Giacomini KM: Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos. 2000 Mar;28(3):329-34. [PubMed:10681378 ]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
- Gene Name
- SLCO1A2
- Uniprot ID
- P46721
- Uniprot Name
- Solute carrier organic anion transporter family member 1A2
- Molecular Weight
- 74144.105 Da
References
- Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612 ]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
- Gene Name
- ABCG2
- Uniprot ID
- Q9UNQ0
- Uniprot Name
- ATP-binding cassette sub-family G member 2
- Molecular Weight
- 72313.47 Da
References
- Gupta A, Zhang Y, Unadkat JD, Mao Q: HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2004 Jul;310(1):334-41. Epub 2004 Mar 8. [PubMed:15007102 ]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostagland...
- Gene Name
- SLCO1B1
- Uniprot ID
- Q9Y6L6
- Uniprot Name
- Solute carrier organic anion transporter family member 1B1
- Molecular Weight
- 76447.99 Da
References
- Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8. [PubMed:12490595 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:25